Omeros/$OMER
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Omeros
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Ticker
$OMER
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
202
ISIN
US6821431029
Website
Omeros Metrics
BasicAdvanced
$196M
-
-$2.64
2.42
-
Price and volume
Market cap
$196M
Beta
2.42
52-week high
$13.60
52-week low
$2.97
Average daily volume
1.2M
Financial strength
Current ratio
1.156
Quick ratio
0.715
Long term debt to equity
-169.04
Total debt to equity
-194.354
Interest coverage (TTM)
-8.22%
Management effectiveness
Return on assets (TTM)
-30.70%
Return on equity (TTM)
123.80%
Valuation
Price to book
-0.91
Price to tangible book (TTM)
-0.91
Price to free cash flow (TTM)
-1.354
Growth
Earnings per share change (TTM)
34.37%
3-year earnings per share growth (CAGR)
-5.60%
What the Analysts think about Omeros
Analyst ratings (Buy, Hold, Sell) for Omeros stock.
Omeros Financial Performance
Revenues and expenses
Omeros Earnings Performance
Company profitability
Omeros News
AllArticlesVideos
Omeros Corporation Reports First Quarter 2025 Financial Results
Business Wire·3 weeks ago
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025
Business Wire·3 weeks ago
Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Omeros stock?
Omeros (OMER) has a market cap of $196M as of June 06, 2025.
What is the P/E ratio for Omeros stock?
The price to earnings (P/E) ratio for Omeros (OMER) stock is 0 as of June 06, 2025.
Does Omeros stock pay dividends?
No, Omeros (OMER) stock does not pay dividends to its shareholders as of June 06, 2025.
When is the next Omeros dividend payment date?
Omeros (OMER) stock does not pay dividends to its shareholders.
What is the beta indicator for Omeros?
Omeros (OMER) has a beta rating of 2.42. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.